Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

ConditionPlacenta Accreta Spectrum

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age20-40

SponsorCairo University

About this trial

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Pregnancy of singleton living fetus

Previous one or more cesarean sections

Gestational age: > 32 weeks

The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".

Disqualifiers

Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….

Any known or reported hypersensitivity to the used medication.

All cases with spontaneous placental separation at laparotomy.

All patients undergoing conservative management of PAS.

Trial design

Design model

Parallel

Treatments tested in this trial

oxytocin
Drug
Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
placebo
Other intervention
IV bolus of normal saline immediately with the uterine incision

Treatment groups

70 Participants

are divided into 2 treatment groups

Group A: Group (A)Experimental treatment 1 intervention

Group B: Group (B)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

Intraoperative blood loss

amount of intraoperative blood loss in patients with PAS disorders undergoing cesarean hysterectomy

Time frame

during operation

Secondary outcomes

operative time

Time frame

during operation

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cairo University

Lead sponsor

Source ClinicalTrials.gov

Apply now